Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2013

01-03-2013 | Letter to the Editor

Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation

Authors: Vladimir Jurisic, Sonja Pavlovic, Natasa Colovic, Milica Colovic

Published in: Medical Oncology | Issue 1/2013

Login to get access

Excerpt

To the editor, …
Literature
1.
Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.PubMedCrossRef
2.
Jurisic V, Colovic N, Terzic T, Djordjevic V, Colovic M. Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukemia: case report and review of literature. Pathol Res Pract. 2012;208(7):420–3.PubMedCrossRef
3.
Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756–61.PubMedCrossRef
4.
Rohr SS, Pelloso LA, Dos Santos Borgo A, de Rezende JG Jr, Silva MR, Yamamoto M, de Lourdes L F Chauffaille M. RARS with fibrosis and del(20q) transformed into ALL. Med Oncol. 2012;29(5):3570–3
5.
Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cell Mol Dis. 2012;49(3–4):170–6.
Metadata
Title
Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation
Authors
Vladimir Jurisic
Sonja Pavlovic
Natasa Colovic
Milica Colovic
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0398-2

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue

Original Paper

High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma

Short Communication

Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China

Original Paper

Attenuated Salmonella typhimurium carrying the hepatocyte growth factor and keratinocyte growth factor genes repairs gastrointestinal mucosal damage caused by chemotherapy

Original Paper

Predictive factors of brain metastasis in patients with breast cancer

Original Paper

Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo

Original Paper

Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits